News

Boyds goes for growth with key business development hire

Boyds, the leading pharmaceutical and biotech product development consultancy, has announced the appointment of business development expert Dr Neil Fish to support the company as it embarks on the next stage of its global expansion.

With over 35 years’ experience in the life sciences industry and an outstanding track record of completing deals, Neil joins the Boyds team as Vice President of Business Development and will be responsible for supporting the company’s continued growth by developing its global client base.

tranScrip’s Outgoing Managing Partner becomes President of the Faculty of Pharmaceutical Medicine

tranScrip is delighted to announce that Dr Flic Gabbay has taken up office as the new President of the Faculty of Pharmaceutical Medicine (FPM). Flic, a co-founder of tranScrip, has spent 4 decades in drug development. Over the last 14 years, she has led tranScrip on multiple innovative projects and drug registrations for over 250 clients.
Being elected President is particularly important to Flic as she Chaired the RCP London Steering Committee which founded FPM as part of the three UK Colleges of Physicians in 1989.

BioIVT Becomes Latest Partner of One Nucleus

Cambridge and London, UK: 11 November 2021

One Nucleus, the not-for-profit Life Science membership group focused primarily on the Greater Cambridge and London Life Sciences Cluster, aims to enable that ecosystem to accelerate the translation of great science and innovation into better patient outcomes. One Nucleus supports companies throughout their life cycle. This includes facilitating engagement between members and expert research partners and providers of key services and insight.

CN Bio and iiCON announce COVID-19 research collaboration

Cambridge and Liverpool, UK, 9 November 2021: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.

Abingworth appoints Jayson Punwani as Partner

London, UK, 8 November 2021 – Abingworth, a leading international life sciences investor, today announced the further strengthening of its investment team with the appointment of Jayson Punwani, PhD, MBA as Partner. Jayson will be based at the firm’s Menlo Park, CA office. He will work with the transatlantic team across all locations, actively seeking new opportunities and supporting existing investments in innovative private and public companies, at all stages of development, as well as those focused on clinical co-development.

Boyds builds on growth plans with clinical operations hire

Leading pharmaceutical and biotech product development consultancy Boyds has further strengthened its clinical operations offering with the appointment of Pippa Bjaaland as a Senior Clinical Research Associate (CRA), as part of an ongoing recruitment drive to grow in-house CRA expertise.

Pippa brings more than five years’ industry experience in clinical operations and joins Boyds from Syneos Health where she was a Senior CRA working on Phase II-IV studies, primarily in oncology. Prior to this, she worked as an in-house CRA at PRA Health Sciences.

On this Day... Marie Curie was born (7th November 1867)

Marie Curie, née Maria Sklodowska, was born in Warsaw on November 7, 1867. She died July 4th 1934.

I could read about this Polish-born French scientist, famous for her work on radioactivity and twice a winner of the Nobel Prize. for. hours! I have referenced her in several of my blog posts already. With Henri Becquerel and her husband, Pierre Curie, she was awarded the 1903 Nobel Prize for Physics. She was later the sole winner of the 1911 Nobel Prize for Chemistry.

A busy month ahead for the Virtual Innovation Centre with two workshops discussing important topics for those Life Science companies becoming more active deal makers:

Growing with Underlying Principles of Drug Development in Mind on 18 November 11.30–12.30 is for early stage companies who need to show their understanding of the underlying principles of drug

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

LONDON and CAMBRIDGE, Mass., Nov.

CellCentric expands presence at Chesterford Research Park

Cambridge, UK, 8th November 2021: Chesterford Research Park is delighted to announce the expansion of existing occupier, CellCentric, within the Mansion House at the heart of the Park. The clinical stage biotechnology company focused on the development of a novel drug for specific cancers has renewed its current lease for Suite 3 in the 19th Century converted manor house, whilst at the same time expanding into Suite 4 within the same building.

My Account